| INTRODUCTION
Liver stiffness measurement (LSM) has quickly grown to become an established first-line tool for assessment of liver fibrosis, especially vibration-controlled transient elastography (VCTE). 1, 2 It is considered quite accurate for ruling out advanced stages of fibrosis or cirrhosis, but less so for ruling them in. 3 The diagnostic performance is known to be affected by a number of factors, and protocols have been devised for minimising their influence, eg, measurements should be made after fasting 4 and B-mode ultrasound should be performed to exclude patients with biliary obstruction or congestive hepatopathy. 3 In addition, aetiology and inflammatory activity must be taken into account when interpreting liver stiffness measurements.
Fatty liver is commonly related to prevalent aetiologies and may drive disease progression. 5, 6 This is particularly relevant for non-alcoholic fatty liver disease or steatohepatitis (NAFLD/NASH), with dramatically increasing numbers as a result of the obesity pandemic. 7, 8 Current research suggests that fatty liver can lessen LSM accuracy 9 and modify cut-offs. 10 Non-invasive surrogates of steatosis staging such as bright echo pattern in conventional ultrasound might help in interpreting results. 11 With the advent of Controlled Attenuation Parameter (CAP) -an ultrasound-based quantitative estimate of hepatic fat incorporated in VCTE -consideration of steatosis in realtime is facilitated. 12 A CAP-based algorithm was explored by Petta et al for use in patients with non-alcoholic fatty liver disease (NAFLD). 13 There is some debate, however, regarding various sources of bias, 14 patient selection and methodological issues. 15 To clarify these issues, and explore aetiology-specific aspects of the putative connection between LSM and CAP, we performed a secondary analysis of individual patient data provided by authors of 19 papers that had originally been collected for determining optimised CAP cut-offs. 16 2 | PATIENTS AND METHODS
| Paper and patient selection
This study is a secondary analysis using the database established for conducting an individual patient data meta-analysis (IPDMA) of Con- Measurements with the Fibroscan XL-probe were not considered.
Roughly speaking, patients were excluded if the body mass index (BMI) was > 35 kg/m² and if the time interval between biopsy and CAP measurement was > 30 days. 16 In the current analysis, patients were further excluded if they had been used for publications on a similar research question, if fibrosis staging was unavailable, if the liver stiffness measurements were unreliable according to established criteria ( < 10 valid measurements, ratio of median to interquartile range ≥ 0.3), 1, 3 if aminotransferases were equal to or above 5 times the upper limit of normal, or the aetiology was unknown.
| Steatosis grading and fibrosis staging
As already described, 16 steatosis was defined according to the number of affected hepatocytes: S0 ( < 5% or 10% depending on the trial), S1 (5% or 10%-33%), S2 (34%-66%) and S3 ( > 66% 
| Objectives of the study
The primary objective is to analyse the influence of steatosis either defined by histology or Controlled Attenuation Parameter on the performance of liver stiffness measurements for distinguishing significant liver fibrosis ( ≥ F2) from mild or non-existent stages. Secondary objectives are determination of disease-specific cut-offs for detection of significant fibrosis, advanced fibrosis ( ≥ F3) and cirrhosis (F4) and analysis of ruling out and ruling in fibrosis/cirrhosis. The initial goal of analysing inflammatory activity could not be performed due to lack of harmonised histological data, but high aminotransferases, indicating inflammatory activity, were part of the exclusion criteria.
| Statistical methods
All analyses were performed with the software R version 3.3.3.
20
Receiver operating characteristic (ROC) analyses made use of the pROC package 21 and optimal cut-offs were determined by maximising the Youden index or applying the minimum criterion of 90% for sensitivity or specificity. Since very wide ranges of cut-offs have been published, 3 we chose optimisations resulting in particularly low ones when optimising negative predictive values (NPV) and high ones for positive predictive values (PPV). LSM was always treated on a logarithmic scale and P-values from linear models comparing multiple groups were corrected using the Bonferroni-Holm method.
A linear mixed-model was used with liver stiffness measurement results as the dependent variable and fibrosis staging, aetiology, steatosis grading, CAP, age, sex, BMI and inflammation status as fixed effects with the trial (ie, "centre effects") as a random term and where P-values for the fixed effects are taken from a Wald chisquare test.
Logistic regression was used to provide estimates and confidence intervals for predictive values and for correct classification of fibrosis stages. In particular, the histologically determined fibrosis category was taken as the dependent variable with the aetiology-specific LSM-based classification and the CAP value as independent variables, including a quadratic term for CAP when necessary. The regression model yields estimates that can be used to determine a probability given a positive/negative LSM result and a particular CAP value, which can be interpreted as a PPV/NPV. Prevalence was taken into account using Bayes' theorem and the observed values of sensitivity and specificity. Smoothing splines were used as a sensitivity analysis to the curves provided by logistic regression.
| RESULTS
Of the initial 2735 patients included in the primary analysis of the CAP-IPDMA, 2058 remained for the current analysis after applying additional exclusion criteria, Figure 1 . Note that 140 patients used by Petta et al 13 to address similar questions to those of the present work were excluded from the analysis. Patient characteristics are presented in Table 1 . Of note is the high prevalence of patients with significant fibrosis or cirrhosis (51% | 991 factor 1.14 (95% CI 1.08 to 1.20, P < 0.001) higher than those with steatosis stages S0 or S1. The corresponding difference in patients with more advanced fibrosis stages was 1.15 (1.04 to 1.27, Figure 2A . When considering NAFLD/NASH alone, a similar result was observed for absent or mild fibrosis, but not for more advanced stages, Figure 2B . These results also hold upon taking into account the slightly different relative proportions of individual fibrosis stages between the S0-S1 and the S2-S3 groups. Linear mixed models, however, do not indicate that steatosis has a significant influence on LSM after taking covariates other than CAP into account (P = 0.056), though the effect becomes significant when comparing S0-S1 with S2-S3 (P = 0.023). Upon including CAP, the effect of steatosis vanishes (P = 0.71) and, although CAP is significant (P = 0.0063), the incremental increase in LSM values is only by a factor 1.0067 (1.0019 to 1.0116) for an increase in CAP by 10 dB/m.
Similarly small elevations in LSM values were seen in HBV and HCV patients with steatosis grades S2 and S3 compared to S0 and S1, though only significantly so for F2-4 HCV patients.
This qualitative behaviour is also seen when detecting advanced fibrosis or cirrhosis. Significant differences may, sometimes, be seen between steatosis grades, but they are always very small ( Figure S1 and Figure S2 ).
| Effect of CAP on correct LSM-classification of fibrosis/cirrhosis
Clearly, interpretation of a non-invasive determination of liver fibrosis should not rely on a biopsy-based characterisation of steatosis.
Therefore, as a second step, we analysed whether CAP can be used to increase the diagnostic performance of LSM. For the entire population, LSM correctly classified 1509 (73%) of the patients as F0-1 vs F2-4 using aetiology-specific, Youden index optimised cut-offs, 
| Effect of CAP on ruling out fibrosis/cirrhosis using LSM
Ruling out fibrosis or cirrhosis is of particular clinical relevance, implying that the negative predictive value must be high.
For ruling out fibrosis in our cohort, NPV was found to be 69% (67% to 72%) at the observed prevalence of 50%, but would reach 88% and 95% at a prevalence of 25% and 10%, respectively. A fairly strong and nonlinear dependence on CAP was seen (P < 0.001), where (Table S1 ), but this results in values that exclude most patients, eg, in our data only 342 patients (17%) are below this cut-off. Using ALT and AST optimised cut-offs, 781 (38%) of the patients are below the cut-off and, at our prevalence, we find an NPV of 70%.
To rule out cirrhosis in our cohort, NPV is 98% (97% to 98%).
There is a nonsignificant dependence on CAP (P = 0. 3.5 | Effect of CAP on detecting fibrosis/cirrhosis using LSM
In another common scenario, LSM is used to "diagnose" fibrosis or cirrhosis and one must contend with false-positive findings. This too is highly dependent on prevalence. PPV for detecting fibrosis was found to be 79% (76% to 82%) at the observed prevalence of 50%, but falls dramatically to 55% and 29% at a prevalence of 25% and Even specificity-optimised cut-offs for cirrhosis, which can be as high as 17.7 kPa for HBV patients (Table S1) (F2-4) or cirrhosis. The grey shaded area denotes a 95% confidence band. HBV, hepatitis B; HCV, hepatitis C; NAFLD/NASH, non-alcoholic fatty liver disease/steatohepatitis for detecting significant fibrosis is 68%. It ranges from 71% for a CAP value of 200 dB/m to 62% for a value of 350 dB/m.
| Diagnostic Flowchart using LSM and accounting for aetiology, ALT, AST and CAP
The above results suggest that LSM be optimised for ruling out cirrhosis and, if possible, significant fibrosis, but imply that "ruling in" will be of limited value. Results can be improved by using specificityoptimised cut-offs and the resulting flowchart is presented in Figure 6. The precise performance will depend strongly on prevalence, but for our cohort, this strategy implied 98% NPV for ruling out cirrhosis, but only 55% PPV for "fairly probable" cirrhosis. The chance of cirrhosis is "quite low" (80% NPV) in a further group with LSM in a grey zone. The chance of significant fibrosis is also "low" (NPV of 70%) for patients below the ALT and AST optimised cut-off. Neither fibrosis nor cirrhosis can be ruled in with acceptable certainties (PPV of 68% or 55%), despite very high, specificity-optimised cut-offs.
The particular values of NPV and PPV will depend on prevalence, but the qualitative statements in the flowchart hold for a wide range of scenarios. A very similar picture emerges when ruling out advanced fibrosis, and the corresponding flowchart is presented in Figure S6 .
| DISCUSSION
This paper provides aetiology-specific cut-offs from a very large cohort and confirms that LSM is a highly accurate tool for ruling out cirrhosis. This holds independent of the CAP value. Significant fibrosis can be ruled out with sufficient certainty only in populations with low prevalence and consideration of CAP can improve the negative predictive value slightly. The accuracy of LSM for detecting significant fibrosis, advanced fibrosis or cirrhosis is limited, due to high false-positive rates, which is especially true for large CAP values.
These results have been summarised in diagnostic flowcharts to facilitate interpretation of LSM in clinical practice.
There is growing pressure to develop reliable tools for screening programs in large populations aimed at detecting fibrosis. 22 The current standard for non-invasive assessment is vibration-controlled
High CAP values imply somewhat lower risk of fibrosis/cirrhosis.
Slight

Relevance of CAP for LSM interpretation Negligible
Optimal cut-off: For the relevant fibrosis cut-off, the sum of sensitivity and specificity (Youden index) were optimised, whereas for positive predictive values (PPV), 90% specificity was required. The asterisk indicates that elevated and normal ALT/AST for HBV/HCV were considered and the lower (higher) cut-off for NPV (PPV) was chosen. See Table S1 for more details on cut-offs. ALT, alanine transaminase; AST, aspartate transaminase; HBV, hepatitis B; HCV, hepatitis C; NAFLD, non-alcoholic fatty liver disease transient elastography, which has already been adopted by international guidelines. 1, 2, 7, 23 Accurate measurement and interpretation rely on consideration of aetiology, inflammatory activity and other covariates, 3 whereas the relevance of steatosis has been a matter of debate. 10, [13] [14] [15] 24, 25 In a large, biopsy controlled NAFLD cohort, Petta et al concluded that CAP should be used to gauge the risk of false-positive LSM results and propose a diagnostic flowchart. 13 We show that steatosis does indeed affect mean LSM values slightly and confirm that CAP can be used as a surrogate in interpreting LSM measurements, but qualify the recommendations from Petta et al in important ways. For one thing, CAP does not sufficiently help increase the probability of correct fibrosis classification for clinical use. Moreover, when focusing on ruling out cirrhosis, consideration of CAP is unnecessary, but does indeed lead to slightly higher negative predictive values for ruling out significant fibrosis. More specifically, aetiology, prevalence and CAP should be taken into account, particularly above a threshold of about 250 dB/m, which also arose as an optimal cut-off for detecting steatosis in this cohort. 16 We choose to focus on positive and negative predictive values also provides a PPV of only 76% even for the lowest CAP tertile.
13
A recent study looking at various combinations of non-invasive methods found comparable PPV for detecting F3-F4. 27 The low PPV indicates the need to develop and use a combination of methods to detect fibrosis and (even more so) cirrhosis that rely on complementary and distinct principles. [27] [28] [29] [30] NPV could be increased for ruling out fibrosis by choosing sensitivity optimised cut-offs. This, however, would result in extremely One weaknesses of the analysis is that it relies on a database collected for assessing CAP alone and not LSM. As such, it is not a meta-analysis, since studies were not selected for the purposes of this analysis, but for the evaluation of CAP. On the other hand, this suggests that the data are more representative of clinical routine than is to be expected from a dedicated "LSM study". However, the sparse data available for aetiologies such as alcoholic and autoimmune/cholestatic liver disease mean that a proportion of patients are underrepresented. This is a void in research that should be filled, though care must be taken to account for specific LSM characteristics of differing aetiologies. Optimising cut-offs and applying them to one and the same cohort is known to lead to overoptimistic estimates. Here, we applied the strategy of adopting a wide "grey zone", so as to have good PPV and NPV, and do not rely on precise optimisation. An inherent fact when collecting individual patient data worldwide is that histological evaluation and biopsy quality may differ between sites as was pointed out in the primary paper, which may be even more relevant in fibrosis staging and requires conversion between scoring systems. 16 
